MYSTERIOUS: 2 | Mind Blowing Facts

EPIX: Preclinical Data on Androgen Receptor N-Terminal Domain Degrader Presented at AACR…

By David Bautz, PhD NASDAQ:EPIX READ THE FULL EPIX RESEARCH REPORT

Benzinga · Apr 30, 2022

QLGN: Secures Worldwide Rights to G4-Selective Cancer Therapeutics…

By David Bautz, PhD NASDAQ:QLGN READ THE FULL QLGN RESEARCH REPORT

Benzinga · Apr 23, 2022

BTAI: IGALMI™ Approved by the FDA…

By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT

Benzinga · Apr 13, 2022

BTAI: Final Countdown to April 5, 2022 PDUFA Date for BXCL501…

By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT

Benzinga · Mar 18, 2022

OPNT: Data from OPNT003 Pharmacodynamic Trial in 2Q22…

By David Bautz, PhD NASDAQ:OPNT READ THE FULL OPNT RESEARCH REPORT

Benzinga · Mar 17, 2022

MDNA: No Read-Through for MDNA11 Based on Nektar Failure…

By David Bautz, PhD NASDAQ:MDNA READ THE FULL MDNA RESEARCH REPORT

Benzinga · Mar 15, 2022

APLIF: U.S. DoD to Provide Over US$10 Million in Funding for ATI-1701…

By David Bautz, PhD OTC:APLIF | TSX:APLI.TO READ THE FULL APLIF RESEARCH REPORT

Benzinga · Mar 3, 2022

EDSA: Phase 3 Trial of EB05 Hits 25% Enrollment…

By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT

Benzinga · Feb 18, 2022

ATE.TO: First Human PK/PD Studies Underway in Otenaproxesul's Post-Operative Pain Program…

By David Bautz, PhD OTC:ATBPF | TSX:ATE.TO READ THE FULL ATE.TO RESEARCH REPORT

Benzinga · Feb 16, 2022

BVXV: Building a Pipeline of VHH Antibody Drug Candidates…

By David Bautz, PhD NASDAQ:BVXV READ THE FULL BVXV RESEARCH REPORT

Benzinga · Feb 10, 2022